Pharma

By Dave Muoio November 2, 2017
North Carolina-based Pneuma Respiratory has announced a fully digital soft mist inhaler device. The inhaler can deliver several different types of medicines directly to the lungs, and by syncing with a mobile app can be used to verify dose delivery in real-time. “What we’ve done is created the first electronically breath-actuated inhaler,” James Bauler, VP of business development at Pneuma...
About the Authors: Bradley Merrill Thompson is a member of the firm at Epstein Becker & Green, P.C. There, he counsels medical device, drug, and combination product companies on a wide range of FDA regulatory issues.  Chris Bergstrom is a digital health leader, for The Boston Consulting Group (BCG). At BCG, he directs digital health initiatives across large payer, provider, med tech, and bio/...
By Dave Muoio October 25, 2017
A newly announced study backed by Takeda Pharmaceuticals, Lundbeck US, and Advocate Health Care will explore the effectiveness of a mobile app designed to improve engagement between patients with major depressive disorder (MDD) and their providers. The investigation will use the Advocate Pathway App to capture the start of or any adjustments to a patient’s antidepressant therapy. Through a...
By Jonah Comstock October 20, 2017
Pharma companies were fairly active in digital health in the third quarter of 2017, especially in the areas of diabetes and respiratory disease. Read on for a round-up of notable events. Diabetes management Abbott Diabetes Care had a big quarter for its Freestyle Libre system, both in the United States and abroad. First, in July, Abbott and Bigfoot Biomedical entered into an agreement to develop...
By Babyforyou.net.ua October 20, 2017
Led by a new commissioner in Dr. Scott Gottlieb, the FDA had a busy few months with a handful of digital and mobile technologies getting cleared in the third quarter of 2017. Consumer-focused diabetes and pain management offerings were prominent, but but by and large the clearances hit a multitude of clinical concerns and, of note, even included the first software-only digital therapeutic....
By Jonah Comstock October 18, 2017
Two years after launching its smoking cessation app Quitter's Circle, pharmaceutical company Pfizer is seeing impressive continued engagement with the app. It's also applying the lessons learned from Quitter's Circle toward other mobile health pursuits — including a recently-launched app for people living with cancer. "We can do surveys right in the app," Mark Pizzini, Pfizer's digital strategy...
By Dave Muoio October 13, 2017
Employees of Chicago-based digital healthcare advertiser Outcome Health allegedly misled the company’s clients by providing inaccurate and manipulated advertisement performance data, according to an investigation published Thursday in the Wall Street Journal. Citing interviews with former employees, advertisers, and internal documents, the Journal wrote that Outcome employees had intentionally...
By Jonah Comstock October 11, 2017
Janssen Research and Development, a Johnson & Johnson subsidiary, will launch the first clinical trial to use its iSTEP technology toolset, which employs smart blisterpacks and a patient-facing smartphone app, by the end of the year. iSTEP, which stands for Integrated Smart Trial and Engagement Platform, has been under development at Janssen for five years. “The mission of Janssen as an...
By Jonah Comstock October 10, 2017
Otsuka, the Japanese pharma company that makes the antipsychotic drug Abilify, has partnered with Australian digital health company Medibio to use Medibio’s system to assess the efficacy of its flagship product. Medibio uses wearable-derived data about heart rate, motion, and sleep to create objective biomarkers for mental illness. “We have proprietary algorithms and technology that use circadian...
By Jonah Comstock October 6, 2017
Pharma companies are as excited as anyone about the shift to value-based care and the ways that technology can enable it, but they’re increasingly skeptical about the speed of that change. At Health 2.0 this week in Santa Clara, California, at a panel moderated by Kian Beyzavi, principal investor at KBeyzavi and Associates, several innovation executives at pharmaceuticals talked about value-based...